On Aug. 19, 2011, the U.S. Food and Drug Administration (FDA) approved Seattle Genetics’ Adcetris (brentuximab vedotin), making it the first drug for Hodgkin’s lymphoma approved in more than 30 years.

Seagen was founded in 1998 as a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. On Mar. 7, 2001 the company launched its Initial Public Offering (IPO) and sold 7 million shares at $7 per share for gross proceeds of $49 million.